Montelukast Aurovitas Spain

Montelukast, the active ingredient in Montelukast Aurovitas Spain, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Aurovitas Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction. It is clinically employed for several respiratory conditions: - Asthma: improves long‑term control and reduces exacerbations. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergen exposure.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Diarrhoea: mild episodes. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or urticaria. - Hepatic enzyme elevation: abnormal liver function tests. - Neuropsychiatric events: mood changes, agitation, or suicidal thoughts. - Stevens‑Johnson syndrome: severe skin reaction (very rare). - Anaphylaxis: life‑threatening hypersensitivity (extremely rare).

Before initiating therapy, clinicians should consider several safety aspects. - Assess asthma control: ensure baseline therapy is optimized. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Review concomitant medications: consider potential drug interactions. - Store at ambient temperature: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to the interaction level.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition may increase montelukast exposure. - Ritonavir: potent CYP3A4 inhibitor can raise plasma levels. - Itraconazole: may elevate montelukast concentrations.

Moderate Interactions (Monitor Closely): - Phenobarbital: enzyme inducer that can reduce efficacy. - Carbamazepine: may lower montelukast levels. - Rifampin: strong inducer, potentially decreasing therapeutic effect. - Warfarin: monitor INR as montelukast may affect anticoagulation. - Oral contraceptives: may require monitoring of hormonal efficacy.